Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis

Fig. 2

CircHMGB2 promotes the proliferation of NSCLC and reshapes the tumor TME. A The proliferation of A549-circHMGB2 and H1299-shcircHMGB2 cells was measured by CCK-8 assay. B The viability of A549-circHMGB2 and H1299-shcircHMGB2 cells was measured by colony formation assays. C and D Nude mice were subcutaneously implanted with A549-control and A549-circHMGB2 cells, and the tumor size was assessed every 3 days. E The proliferation of LLC-circHMGB2 cells was measured by CCK-8 assay. F The viability of LLC-circHMGB2 cells was measured by colony formation assays. G and H C57BL/6 mice were subcutaneously implanted with LLC-control and LLC-circHMGB2 cells, and the tumor size was assessed every 3 days. I The immune cell profiles of subcutaneous tumors derived from LLC-control and LLC-circHMGB2 cells were assessed by flow cytometry. J IHC staining of CD8+ T cells, DCs, and NK cells in subcutaneous tumors derived from LLC-control and LLC-circHMGB2 cells. K The infiltration of CD8+ T cells, DCs and NK cells in 120 NSCLC tissues divided into circHMGB2low and circHMGB2high groups was assessed by IHC. Data are presented as the means ± SD; n = 3, *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant

Back to article page